Canadian CANNAINVESTOR Magazine July / August 2017 - Page 62


With OPSEU now covering the cost of medical marijuana (up to $3,000/yr) for its members and at least one LP (Aphria) in negotiations with at least one Local Union, one can speculate that it is a matter of time before medical marijuana is covered by employer, private, and perhaps even government benefits.

The day our May issue was released, shares of Aurora Cannabis Inc (TSXV:ACB; OTC:ACBFF) were halted. The next day, on May 26, the halt was lifted and the news - their major expansion into Germany. Spiro Sertsis has an article dedicated this month on Germany that I encourage you to read. On that same day, Health Canada announced the game-changing news governing the industry in preparation of the adult recreational market and in particular how it will be fast tracking those in the latter stages of the ACMPR processes including when a “grow and cultivate” license will be granted. Our May issue included content on ACB (including as a case study); the importance of Germany; and perhaps consider investing in companies in the latter stage of the ACMPR applicant process. CANNAINVESTOR Magazine connects the dots for our stakeholders as we sift through all of that data and transform it into meaningful value added forward looking information. It is impossible to get it right every time of course and those missteps feed into our ongoing modelling.

We all know CBD appears crucial for many medical applications. With this focus on CBD, how long will it before we see production from Cannabis Ruderalis? Industrial Hemp is another source of CBD but also has several other applications ranging from hempcrete to food items to textiles. In past articles, we have emphasized the importance for an LP to consider a Hemp line as it affords branding and marketing that are otherwise forbidden in the cannabis industry. The Hemp market also dwarfs the cannabis market. ACB announced a strategic investment in Hempco Food and Fibre Inc (TSXV:HEMP; OTC:HMPPF). HEMP is no stranger to investors in this industry as in November they announced that they would be utilizing the patented technology of Lexaria Bioscience Corp (CSE:LXX; OTC:LXRP). This is where it may, in time, get very interesting. Lexaria has entered into a Joint Venture with Neutrisci Intl Inc (TSXV:NU; OTC:NRXCF) “to produce and commercialize a line of healthy, sugar-free, edible cannabinoid mouth-melt products which will utilize Lexaria's patented technology and Neutrisci's proprietary pterostilbene tablet form factor”. NU has stated it is looking to partner with LPs; LXX has entered into an agreement with the National Research Council of Canada. Lexaria has been the focus of past case studies and coverage and is this month’s feature company for good reason. Another interesting one is a company that we introduced previously but the time appears right for a quick revisit: NYM Neutraceuticals Inc (CSE:MYM; OTC:MYMMF). MYM is included in Case Study#3 this month.